Relay Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Relay Therapeutics R&D Spending Growth & History (RLAY)
Relay Therapeutics's r&d spending was $261.4M for fiscal 2025.
View full Relay Therapeutics company overviewRelay Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $261.4M | −$57.7M | −18.08% |
| 2024 | 2024-12-31 | $319.1M | −$10.9M | −3.31% |
| 2023 | 2023-12-31 | $330.0M | $83.7M | +33.96% |
| 2022 | 2022-12-31 | $246.4M | $73.7M | +42.69% |
| 2021 | 2021-12-31 | $172.7M | $72.8M | +72.89% |
| 2020 | 2020-12-31 | $99.9M | $29.6M | +42.04% |
| 2019 | 2019-12-31 | $70.3M | — | — |
Relay Therapeutics quarterly r&d spending
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $76.5M | $12.6M | +19.70% |
| Q1 2026 | 2026-03-31 | $70.6M | −$3.2M | −4.40% |
| Q4 2025 | 2025-12-31 | $55.4M | −$12.7M | −18.60% |
| Q3 2025 | 2025-09-30 | $68.3M | −$8.4M | −10.91% |
| Q2 2025 | 2025-06-30 | $63.9M | −$28.1M | −30.54% |
| Q1 2025 | 2025-03-31 | $73.8M | −$8.6M | −10.43% |
| Q4 2024 | 2024-12-31 | $68.1M | −$9.4M | −12.16% |
| Q3 2024 | 2024-09-30 | $76.6M | −$4.9M | −5.98% |
| Q2 2024 | 2024-06-30 | $92.0M | $3.8M | +4.30% |
| Q1 2024 | 2024-03-31 | $82.4M | −$424,000 | −0.51% |
| Q4 2023 | 2023-12-31 | $77.5M | $10.2M | +15.19% |
| Q3 2023 | 2023-09-30 | $81.5M | $14.6M | +21.81% |
| Q2 2023 | 2023-06-30 | $88.2M | $27.7M | +45.76% |
| Q1 2023 | 2023-03-31 | $82.8M | $31.2M | +60.31% |
| Q4 2022 | 2022-12-31 | $67.3M | $15.4M | +29.61% |
| Q3 2022 | 2022-09-30 | $66.9M | $21.9M | +48.75% |
| Q2 2022 | 2022-06-30 | $60.5M | $15.4M | +34.03% |
| Q1 2022 | 2022-03-31 | $51.7M | $21.0M | +68.73% |
| Q4 2021 | 2021-12-31 | $51.9M | $19.8M | +61.60% |
| Q3 2021 | 2021-09-30 | $45.0M | $20.6M | +84.50% |
| Q2 2021 | 2021-06-30 | $45.1M | $23.5M | +108.38% |
| Q1 2021 | 2021-03-31 | $30.6M | $8.9M | +41.12% |
| Q4 2020 | 2020-12-31 | $32.1M | — | — |
| Q3 2020 | 2020-09-30 | $24.4M | $6.1M | +33.52% |
| Q2 2020 | 2020-06-30 | $21.7M | $5.3M | +32.13% |
| Q1 2020 | 2020-03-31 | $21.7M | — | — |
| Q3 2019 | 2019-09-30 | $18.3M | — | — |
| Q2 2019 | 2019-06-30 | $16.4M | — | — |
Relay Therapeutics r&d spending trends
Over the last five fiscal years, Relay Therapeutics's r&d spending increased from $99.9M to $261.4M, a change of $161.5M. The latest reported quarter, Q2 2026, shows $76.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relay Therapeutics source filings ↗